Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

In March 2026, the Company reported the following: The Company expects presentation of more detailed results for the seven (7) Cohort A patients at a future oncology conference. INVINCIBLE-3 Study: Phase 3 open-label, randomized study testing INT230-6 as monotherapy compared to the SOC drugs in second- and third-line treatment for specific soft tissue sarcoma subtypes. In March 2025, the Company paused new site activations and patient enrollments due to funding constraints. Before this pause, the trial had ...